Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a
Tweet Send to a Friend
Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
